Haier Biomedical Secures Top Two Rankings in Euromonitor Report on Global Life Science Lab Equipment Sales
Haier Biomedical (SHA: 688139) has become the top Chinese brand in global life science laboratory equipment sales, leading in overseas markets. This performance, revealed in Euromonitor International’s 2025 report, underscores Haier Biomedical’s position as a major global player and demonstrates the success of its three-phase international expansion strategy with a compound annual growth rate (CAGR) exceeding 20%.
According to Euromonitor International, an independent market research firm trusted by global industry players, Haier Biomedical secured the top position based on total revenue from global sales and overseas sales in the life science lab equipment category among Chinese brands. The ranking covers the entire global market and reflects Haier Biomedical’s ability to compete with established international manufacturers at the highest level.
For international partners, this achievement holds significant importance. In an industry reliant on equipment reliability, regulatory compliance, and long-term service support, independent market leadership verification boosts confidence for institutions evaluating suppliers.
Haier Biomedical’s global expansion began with targeted projects collaborating with international organisations such as UNICEF and the World Health Organization to address unmet needs, while establishing a strong position in solar-powered vaccine storage solutions. It has since expanded its distribution network to 160 countries through over 800 active partners. Currently, Haier Biomedical is strengthening local operational capabilities in strategic regions, including warehousing, sales, marketing, product planning, and research and development (R&D).
Haier Biomedical now operates overseas R&D centres in the UK, Italy, and Japan, each focusing on specific product lines such as centrifuges, cold chain and automation solutions, incubators, and biosafety cabinets. In the UK and mainland Europe, product experts provide on-site support for GMP compliance, air safety, and sample purification. These efforts reinforce Haier Biomedical’s role as a strategic partner in laboratory workflow management. Service standards developed in the US and UK are being replicated across other regions, including the EU, Southeast Asia, and South Asia.
In Q1 2026, Haier Biomedical’s revenue surged over 50% in Germany, Australia, and Canada. Meanwhile, Eastern Europe, South Asia, and Brazil each reported annual growth exceeding 100%. Sales volumes for centrifuges and incubators doubled compared to the same period last year. In the pharmaceutical sector, Haier Biomedical is part of the supply chain for leading global pharmaceutical companies in Switzerland, Germany, Denmark, Italy, Singapore, the US, Israel, and India. Additionally, its Ultra Energy series secured all eight top spots in the US Energy Star rankings, making it the highest-selling product line in the segment.
Looking ahead, Haier Biomedical plans to deepen local market investments and expand its product portfolio. This strategy aims to help global bio-pharmaceutical and life science laboratories enhance operational efficiency and sustainability, aligning with its vision to become a global leader in integrated life science equipment and intelligent productivity platforms.